After targeting struggling biotechs, Tang’s Concentra shifts gears with unsolicited bid for LianBio

Ayisha Sharma

News Reporter

Tang Capital Management has made its fifth unsolicited acquisition bid of the year, this time for US-Chinese company LianBio. The choice of target marks a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After targeting struggling biotechs, Tang’s Concentra shifts gears with unsolicited bid for LianBio

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Jazz wins approval for bispecific in biliary tract cancer

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

Af­ter tar­get­ing strug­gling biotechs, Tang’s Con­cen­tra shifts gears with un­so­licit­ed bid for Lian­Bio

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

After targeting struggling biotechs, Tang’s Concentra shifts gears with unsolicited bid for LianBio

Jazz wins approval for bispecific in biliary tract cancer

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?